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1914to allow independent verification.
Second, comparing crude rates with
age-standardized rates is invalid. This
is because melanoma rates have
been increasing in older people but
decreasing in younger people during
a period in which more Australians are
surviving to old age. This means that
crude melanoma rates calculated for
the year 1982 relate to an entirely
different population structure versus
those calculated for 2011. Without
properly accounting for these changes,
the differences between crude and
standardized rates are uninterpretable,
and no valid comparisons can be made.
We considered the issue of popula-
tion dilution in our article, and we
referenced Dr. Czarnecki’s original
article positing his hypothesis
(Czarnecki, 2014). We also referenced
the subsequent paper by Baade et al.
(2015) that elegantly disproved it. In
their article, Baade et al. modeled
melanoma incidence in Australia under
the full range of hypothetical scenarios
that might explain Australia’s popula-
tion growth between 1982 and 2011—
that is, from being 100% attributable
to migration to 0% attributable to
migration. Regardless of the assumed
level of migration, the decline in age-Abbreviations: cAMP, cyclic adenosine monophosph
summary odds ratio; WT, wild-type
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Journal of Investigative Dermatology (2016), Volumstandardized melanoma incidence in
Australia was apparent across all
scenarios, from which the authors
concluded that there is “strong evi-
dence against the hypothesis that the
observed decrease in melanoma inci-
dence among young Australians since
the mid-1990s can be explained solely
by the increasing overseas migration
and any resultant lowering of the ‘at
risk’ population in Australia.” We agree
with their conclusion.
In summary, we agree that popula-
tion dilution is of interest and may
explain some of the decline in the
Australian melanoma incidence rates,
but we disagree with the assertion that
melanoma incidence is rising in young
susceptible Australians. As argued by
others (Baade et al., 2015), the timing
of the changes in melanoma incidence,
coupled with the divergent trends
among younger and older Australians,
are consistent with birth cohort and
period effects that are best explained
by primary prevention campaigns that
commenced nationally in the 1980s.
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Skin pigmentation is due to the accu-
mulation of eumelanin, which is
brown-black pigment and photo-
protective, and pheomelanin, which is
yellow-red pigment and may promote
carcinogenesis (Valverde et al., 1995).
The melanocortin-1 receptor (MC1R)
gene regulates the amount and type of
pigment production and is a major
determinant of skin phototype (Garcia-Borron et al., 2005; Valverde et al.,
1995). Binding of a-melanocyte stimu-
lating hormone to MC1R stimulates the
enzymatic activity of adenylate cyclase
enzyme, thereby elevating intracellular
cyclic adenosine monophosphate
(cAMP) levels. MC1R is highly poly-
morphic, especially in Caucasians:
more than 200 coding region variants
have been described to date (Garcia-
Borron et al., 2014; Gerstenblithet al., 2007; Perez Oliva et al., 2009).
Six variants—D84E, R142H, R151C,
I155T, R160W, and D294H—have
been designated as “R” alleles because
of their strong association with the “red
hair color” phenotype characterized by
red hair, fair skin, freckles, and sun
sensitivity. The V60L, V92M, and
R163Q variants are found to have a
weaker association with the red hair
color phenotype and have been desig-
nated as “r” alleles (Garcia-Borron
et al., 2014; Raimondi et al., 2008).
Previous studies demonstrated that
several alleles are associated with
phenotypic characteristics and that
MC1R variants are associated with both
Table 1. Summary odds ratios for the association between combined
MC1R variants and phenotypic characteristics
Phenotypic characteristic MC1R Studies/control SOR (95% CI) I2 (%)3 P-value3
Hair color—fair versus dark1 Wild-type 13/1,371 1.00 (reference)
Any variant 13/2,758 1.91 (1.38e2.65) 59 <0.01
1 variant 13/1,991 1.55 (1.12e2.15) 39 0.07
2þ variants 13/767 3.32 (2.34e4.72) 62 <0.01
Hair color—red versus others Wild-type 7/705 1.00 (reference)
Any variant 7/1,474 3.54 (1.91e6.55) 0 0.80
1 variant 7/1,016 1.18 (0.57e2.44) 0 0.83
2þ variants 7/458 10.17 (5.28e19.58) 0 0.77
Eye color—fair versus dark2 Wild-type 14/1,530 1.00 (reference)
Any variant 14/2,832 1.12 (0.96e1.30) 12 0.33
1 variant 14/2,079 1.11 (0.94e1.32) 10 0.35
2þ variants 14/753 1.16 (0.93e1.45) 0 0.80
Skin type—I, II versus III, IV Wild-type 14/1,540 1.00 (reference)
Any variant 14/3,046 2.26 (1.81e2.83) 49 0.02
1 variant 14/2,211 1.95 (1.51e2.53) 41 0.06
2þ variants 14/8,35 3.58 (2.68e4.78) 42 0.05
Freckles—yes versus no Wild-type 9/1,067 1.00 (reference)
Any variant 9/2,257 2.52 (1.99e3.20) 33 0.16
1 variant 9/1,528 2.00 (1.52e2.64) 36 0.13
2þ variants 9/729 4.47 (3.25e6.15) 38 0.12
Significant ORs and P-values are in bold.
Abbreviations: CI, confidence intervals; MC1R, melanocortin-1 receptor; OR, odds ratio; SOR,
summary odds ratio.
1Fair hair colors were red, blond, dark blonde, light brown. Dark hair colors were brown, black, dark
brown.
2Fair eye colors were blue, green, gray, hazel. Dark eye colors were brown, black.
3I2 andQ test P-value aremeasures of between-study heterogeneity (see SupplementaryMethods online).
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cancer (Han et al., 2006; Pasquali et al.,
2015; Scherer et al., 2008; Tagliabue
et al., 2015) with a stronger role
for darker-pigmented populations, sug-
gesting that nonpigmentary pathways
link MC1R with skin cancer develop-
ment. Because the role and strength of
each MC1R variant in determining
specific phenotypic characteristics and
the red hair color phenotype remains
unclear, we performed a pooled anal-
ysis of individual-level data from the
M-SKIP project, described in full else-
where (Raimondi et al., 2012). We
selected from the M-SKIP database all
5,366 cancer-free controls with MC1R
gene sequenced and information on at
least one of the following phenotypic
characteristics: hair color, eye color,
skin type, and freckles, thus including
16 independent studies from 18
publications (Supplementary Table S1
online).
We found greater summary odds
ratios (SORs) for carriers of two MC1R
variants compared with carriers of only
one variant allele (Table 1).Furthermore carriage of any MC1R
variant, one variant and two or more
variants, compared with not having
such variants (i.e., wild-type [WT]
subjects), was significantly associated
with fair hair color, skin type I/II, and
presence of freckles. Red hair color was
significantly associated with carrying
any MC1R variant (SOR; 95% confi-
dence interval: 3.54; 1.91e6.55) and
with carrying two or more variants
(SOR; 95% confidence interval: 10.17;
5.28e19.58), but not with carrying one
MC1R variant (SOR; 95% confidence
interval: 1.18; 0.57e2.44). No signifi-
cant association was observed for light
eye color and MC1R. Sensitivity ana-
lyses indicated that the observed
between-study heterogeneity may be
attributable to single studies: when we
excluded the studies that were outliers,
we obtained similar pooled odds ratios
as the original ones, but no longer with
evidence of heterogeneity (results not
shown). No evidence of publication
bias was found by Egger’s test. All the
investigated MC1R variants compared
with WT subjects were positivelyassociated with skin type I/II and
freckles (Supplementary Table S2 on-
line). The three variants that seemed to
play the most important role in skin
type determination and the presence of
freckles were D84E, R151C, and
D294H. Red hair color was signifi-
cantly associated with all MC1R vari-
ants except for V92M and R163Q.
We visualized the associations
between hair color, eye color, skin type,
freckles, and the three main studied
geographical areas by multiple corre-
spondence analysis (Supplementary
Figure S1a or b online). A two-
dimensional multiple correspondence
analysis solution, with dimension 1 on
the horizontal axis and dimension 2 on
the vertical axis, was considered the
most adequate because the first and
second dimension presented Benzecri-
adjusted inertias of 85.31% and
11.31%, respectively (Supplementary
Table S3 online), accounting for
96.62% of the total association. The
extreme red hair color phenotype (red
hair, skin type I, and freckles) was
associated either with carrying at least
two MC1R variants (Supplementary
Figure S1a) or with the presence
of major penetrant (“R”) alleles
(Supplementary Figure S1b). We sug-
gest that dimension 1 can be inter-
preted as a “pigmentation score”
because it differentiates well between
dark and fair phenotypic characteris-
tics. The median pigmentation score
increased with increasing number of
MC1R variants, and for single MC1R
variants it was higher (P < 0.0001)
compared with WT subjects
(Supplementary Figure S2 online).
Seven of the nine MC1R variants
analyzed in this study, V60L, D84E,
R142H, R151C, I155T, R160W, and
D294H, are clearly hypomorphic with
significant reduction in cAMP signaling
potential (Beaumont et al., 2007;
Herraiz et al., 2012; Kadekaro et al.,
2010; Scott et al., 2002). Within this
group of variants, the lowest SOR for
red hair, skin type I/II, or freckles cor-
responds to V60L. Interestingly, this
variant was also the one with the
smallest functional impairment in terms
of coupling to the cAMP pathway,
when the seven variants analyzed here
were compared under identical exper-
imental conditions (Herraiz et al.,
2012).www.jidonline.org 1915
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1916Results also showed that V92M and
R163Q behave as “r” alleles, with a
weak albeit significant association with
cutaneous phenotypic traits. In heter-
ologous systems, V92M has been
reported to display either a slight
functional impairment (Herraiz et al.,
2012) or normal coupling to the
cAMP pathway (Beaumont et al.,
2007), whereas R163Q apparently
signals as efficiently as WT. Therefore,
it appears that the ability of V92M or
R163Q to activate the cAMP pathway
is similar, if not identical to WT.
This suggests that other mechanisms
account for their association with
cutaneous phenotypic characteristics,
for example, V92M or R163Q might
impair functional coupling to signaling
module(s) different from the cAMP
cascade. MC1R promiscuously binds
to a variety of intracellular partners
with signaling potential and this ability
might depend on WT conformation.
However, little is known as to the ef-
fects of other variants on MC1R bind-
ing to its various protein partners, and
the phenotypic consequences of such
molecular interactions also remain
largely unknown. Further research is
needed to understand the scaffolding
properties of MC1R, the functional
consequences of the formation of
signaling complexes orchestrated by
the receptor, and the effects on these
processes of the myriad of natural
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of L’Aquila, Italy), José C. Garcı́a-Borrón (Univer-
sity of Murcia, Spain), Jiali Han (Brigham and
Women’s Hospital and Harvard Medical School,
Boston, MA), Peter A. Kanetsky (Department of
Cancer Epidemiology, H. Lee Moffitt Cancer
Center and Research Institute, Tampa, FL), Maria
Teresa Landi (National Cancer Institute, NIH,
Bethesda, MD), Julian Little (University of Ottawa,
Canada), Julia Newton-Bishop (University of
Leeds, UK), Francesco Sera (UCL Institute of Child
Health, London, UK); Consultants: Saverio Caini
(ISPO, Florence, Italy), Sara Gandini and Patrick
Maisonneuve (European Institute of Oncology,
Milan, Italy); Participant Investigators: Albert
Hofman, Manfred Kayser, Fan Liu, Tamar Nijsten,
and Andre G. Uitterlinden (Erasmus MC Univer-
sity Medical Center, Rotterdam, The Netherlands),
Rajiv Kumar and Dominique Scherer (German
Cancer Research Center, Heidelberg, Germany),
Tim Bishop, Julia Newton-Bishop, and Faye Elliott
(University of Leeds, UK), Eduardo Nagore (Insti-
tuto Valenciano de Oncologia, Valencia, Spain),
DeAnn Lazovich (Division of Epidemiology and
Community Health, University of Minnesota,
MN), David Polsky (New York University School
of Medicine, New York, NY), Johan Hansson and
Veronica Hoiom (Karolinska Institutet, Stockholm,
Sweden), Paola Ghiorzo and Lorenza Pastorino
(University of Genoa, Italy), Nelleke A. Gruis and
Jan Nico Bouwes Bavinck (Leiden University
Medical Center, The Netherlands), Paula Aguilera,
Celia Badenas, Cristina Carrera, Pol Gimenez-
Xavier, Josep Malvehy, Miriam Potrony, Susana
Puig, Joan Anton Puig-Butille, Gemma Tell-Marti
(Hospital Clinic, IDIBAPS and CIBERER, Barce-
lona, Spain), Terence Dwyer (Murdoch Childrens
Research Institute, Victoria, Australia), Leigh
Blizzard and Jennifer Cochrane (Menzies Institute
for Medical Research, Hobart, Australia), Ricardo
Fernandez-de-Misa (Hospital Universitario Nues-
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In our previous experience, a high
consistency of BRAF and NRAS muta-
tion patterns was observed between
primary tumors and lymph node me-
tastases in patients with advancedmelanoma (Colombino et al., 2012).
Conversely, increasing rates of discrep-
ancies in BRAF/NRAS mutation pat-
terns were found between primary
melanomas and metastases in other
sites (brain or, mostly, skin) (Colombinoet al., 2012). When the distribution of
BRAF/NRAS mutations was evaluated
in a larger cohort, the high rate of
consistency in sequence variations of
these two genes was further confirmed
between primary melanomas and
lymph node metastases (142/156; 91%)
(Colombino et al., 2013; unpublished
data). However, intraindividual hetero-
geneity of BRAF mutations has beenwww.jidonline.org 1917
